EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study

Adria Rose iD, Rohini R Datta iD, Costanza Di Chiara iD, Pierre-Philippe Piché-Renaud iD, Shaun K Morris iD

Pediatric Pulmonology · 2026-06 · 61 (6)

DOI: 10.1002/ppul.71696 ↗

At a glance

Journal article in Pediatric Pulmonology, published online on 2026-06-10. Written by Adria Rose and 4 co-authors. Institution: Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada. Major MEDLINE topics: Respiratory Syncytial Virus Infections, Pediatricians, Health Knowledge, Attitudes, Practice, Attitude of Health Personnel. 34 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Public Health Agency of Canada's Immunization Partnership Fund.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Introduction

New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.

Methods

In March−April 2024, Pediatricians Alliance of Ontario newsletter subscribers ( n = 1566) were invited to complete an online survey on RSV knowledge and attitudes. Descriptive analyses with a complete‐case approach assessed responses.

Results

Of 117 responses (7% response rate), we retained 104 confirmed as from pediatricians with complete demographic data, including 81% (84/104) general pediatricians and 19% (20/104) subspecialists. Most worked in primary care (40%; 42/104), community hospitals (32%; 33/104), and urban centers (63%; 65/104), and had ≥ 10 years' experience (81%; 83/104). They had high awareness of provincial recommendations (91%; 94/103) and knowledge of severe RSV disease risk factors (Figure 2). While 83% (82/99) always recommended palivizumab to eligible patients, only 34% (34/99) reported that all eligible patients always received it. Over 90% were likely to recommend nirsevimab (91%; 89/98), but 66% (65/98) expected to administer it. Top anticipated barriers included the introduction of a new product (69%; 25/36) and concern for adverse effects (69%; 41/59). The likelihood of recommending a maternal vaccine over nirsevimab was 45% (44/98), while 44% (43/98) were neutral.

Conclusion

Ontario pediatricians were knowledgeable and supportive of RSV prevention products. However, they have experienced barriers with palivizumab, and they anticipated barriers with nirsevimab and the maternal RSV vaccine. As other jurisdictions look to implement new RSV prevention products, acknowledging and addressing anticipated barriers may promote acceptance and use.

Subjects

MeSH terms (MEDLINE)

Respiratory Syncytial Virus InfectionsPediatriciansHealth Knowledge, Attitudes, PracticeAttitude of Health PersonnelRespiratory Syncytial Virus VaccinesHumansCross-Sectional StudiesOntarioFemaleMaleAntiviral AgentsPalivizumabAdultSurveys and QuestionnairesMiddle AgedPractice Patterns, Physicians'

Author keywords

Canadabarriersimmunizationrespiratory syncytial virusvaccine

Substances

Antiviral AgentsPalivizumabRespiratory Syncytial Virus Vaccines

Authors and institutions

  • Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Division of Infectious Diseases, The Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

ORCID profiles: Adria Rose, Rohini R Datta, Costanza Di Chiara, Pierre-Philippe Piché-Renaud, Shaun K Morris

Funding

  • Public Health Agency of Canada's Immunization Partnership Fund

Cite

APA

Rose, A., Datta, R. R., Di Chiara, C., Piché-Renaud, P. P., & Morris, S. K. (2026). Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study. Pediatric Pulmonology, 61(6). https://doi.org/10.1002/ppul.71696

Vancouver

Rose A, Datta RR, Di Chiara C, Piché-Renaud PP, Morris SK. Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study. Pediatric Pulmonology. 2026;61(6). doi:10.1002/ppul.71696

BibTeX
@article{Rose2026,
  author = {Rose, Adria and Datta, Rohini R and Di Chiara, Costanza and Piché-Renaud, Pierre-Philippe and Morris, Shaun K},
  title = {Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {6},
  doi = {10.1002/ppul.71696}
}
Start for free →